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Abstract
It is now commonly admitted that the so-called (most) neglected tropical diseases have been given
little attention. According to World Health Organization, neglected diseases are hidden diseases
as they affect almost exclusively extremely poor populations living in remote areas beyond the
reach of health service. The European Parliament recognised that, to our shame, Neglected
Diseases have not received the attention they d e s e r v e  f r o m  E U  a c t i ons. In the Millennium
Development Goals they were given very little attention and mentioned just as other disease.
Investing in drugs for these diseases is thought to be not marketable or profitable. However,
despite their low mortality, neglected diseases are causing severe and permanent disabilities and
deformities affecting approximately 1 billion people in the world, yielding more than 20 millions of
Disability Adjusted Life Years (56.6 million according to Lancet's revised estimates) and important
socio-economic losses. Urgent pragmatic and efficient measures are needed both at international
and national levels.
1. Introduction
At the dawn of the third millennium, while human rights
and health equity are on all international agendas, mil-
lions of forgotten people are suffering from a dozen of
neglected diseases (NDs). According to The World Health
Organization (WHO), NDs are hidden diseases as they
affect almost exclusively extremely poor populations liv-
ing in remote areas beyond the reach of health services
[1]. The European Parliament recognised that "to our
shame, Neglected Diseases have not received the attention
they deserve from EU actions" [2]. Focusing on the "big
killers" like HIV/AIDS, malaria and tuberculosis, the Mil-
lennium Development Goals (MDG) and other initiatives
have generally given very little attention to the most
neglected diseases, often mentioned just as "other dis-
ease" (Table 1)[3]. Criticizing the "inertia" and the delay
taken in the response to the infectious diseases, the
humanitarian organization Médecins sans Frontière
(MSF) has been continuously attracting the international
attention to stimulate more interest in the development
and provision of treatments for the most neglected dis-
eases [4]. Meanwhile, beyond mortality figures, NDs con-
tinue to cause severe and permanent disabilities and
deformities affecting more than a billion people in the
world and breeding millions of disability adjusted life
years (DALYs) and important economic losses. Indeed,
lymphatic filariasis(LF), leishmaniasis, schistosomiasis,
Buruli ulcer, cholera, cysticercosis, dracunculiasis (guinea-
worm disease), foodborne trematode infections, hydati-
dosis, soil-transmitted helminthiasis (ascariasis, trichuria-
sis, hookworm diseases), trachoma, trypanosomiasis
(sleeping sickness), onchocerciasis, Chagas disease, den-
gue and others [Additional file 1] are responsible for
impaired childhood growth, mental retardation, blind-
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ness, amputation and diverse disability conditions and
hence they are impeding human development of many
countries of Africa and Latin America (Tables 2 and
3)[1,5-8]. The situation being commonly admitted, it
remains that urgent and efficient strategies are needed at
local, national and international levels in order to reduce
the growing burden of these diseases of the poor.
2. Neglected diseases afflicting marginalised 
populations: Challenges and perspectives
Neglected Diseases are given low priority because they
have low mortality, they occur almost exclusively in poor
developing countries and essentially, because they offer
negligible marketable and profitable issues. As stressed by
the European Parliament Report in 2005, "No research is
currently being carried out into the most neglected dis-
eases which mainly affect developing countries...there is a
chronic shortage of investment in research and develop-
ment in poverty-related diseases and in the developing
countries themselves to obtain medicines which meet the
needs of those countries" [2].
For the pharmaceutical industry, which carries out the
main research and development for new drugs, it is too
costly and risky to invest in drugs for neglected diseases
occurring essentially in low-income countries where pub-
lic spending on drugs is less than US$6 (sub-Saharan
Africa) compared to around US$ 240 spent in countries of
the Organization for Economic Cooperation and Devel-
opment (OECD) [9]. It is estimated that, less than 10% of
the world's biomedical research funds are dedicated to
problems dealing with 90% of the world's burden of dis-
ease and, of all drugs in development for all neglected dis-
eases in 1999–2000, 18 R&D projects were clinical
development, compared to 2100 compounds for all other
diseases [1,2]. Between 1975 and 2004, among the 1556
new molecules of drugs marketed in the world, only 21
were intended for the neglected diseases (8 for malaria, 3
for tuberculosis and only 10 for the whole set of most
neglected diseases)[4]. Another study found that, of the
1393 new chemical entities marketed between 1975 and
1999, only 16 were for tropical diseases and tuberculosis,
yielding a 13-fold greater chance for a drug to be marketed
for central-nervous-system disorders or cancer than for a
neglected disease (Table 4) [9].
Despite the dilemma created by the pharmaceutical
industry (treatment-profit), the responsibility is shared by
Table 1: The Millennium Project [4]
Millennium Development Goals UN Millennium Project task forces
1. Reduce extreme poverty and hunger by half relative to 1990 1. Poverty and economic development
2. Achieve universal primary education 2. Hunger
3. Promote gender equality & empowerment of women 3. Education and gender equality
4. Reduce child mortality by two-third relative to 1990 4. Child and maternal health
5. Improve maternal health, including reducing maternal mortality by 
three-quarters relative to 1990
5. HIV/AIDS, malaria, tuberculosis, and access to essential medicines
6. Prevent spread of HIV/AIDS, malaria, and other diseases 6. Environmental sustainability
7. Ensure environment sustainability 7. Water and sanitation
8. Develop a global partnership for development 8. Improving the lives of slum dwellers 9. Trade 10. Science, technology, 
and innovation
Table 2: The burden of neglected diseases according to WHO Report 2002 [1]
Disease Deaths Burden in DALYs
Lymphatic filariasis 0 5 654 000
Soil-transmitted helminthiasis 12 000 4 706 000
Kala-azar 2 357 000
Trachoma 0 2 329 000
Leishmaniasis 51 000 2 400 000
Schistosomiasis 15 000 1 760 000
Sleeping sickness 48 000 1 600 000
Onchocerciasis 0 987 000
Dengue 700 000
Chagas disease 14 000 649 000
Leprosy 6 000 177 000
Buruli ulcer 100 000
Guina-worm 100 000International Journal for Equity in Health 2007, 6:20 http://www.equityhealthj.com/content/6/1/20
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other decision makers. At the global level, international
solidarity and public-private partnerships are needed to
tackle the problems of shortage and lack of treatments,
resistance and the need for new drugs and vaccines. More
initiatives are needed to support the projects already
launched such as Global Alliance for Vaccines and Immu-
nization (GAVI), The Human Hookworm Vaccine initia-
tive (HHVI), the Foundation for Innovative New
Diagnostics (FIND), the Drug for Neglected Diseases Ini-
tiative (DNDi), The USAID funded program on integrated
control of seven of the most prevalent neglected tropical
diseases (trachoma, hookworm, ascariasis, trichuriasis,
onchocerciasis, schistosomiasis and lymphatic filariasis)
and others [1,2,10-12].
However, this international strategy is insufficient with-
out the national and local implication. National health
decision makers, non governmental organizations
(NGOs), research institutions, community groups and
individuals must adhere to these global initiatives. Many
countries, being heavily indebted, affect less than 1% of
the national global budget to health, and few govern-
ments are putting science, technology, and innovation at
the centre of their strategies and, in the meantime, war
and conflicts are financed at the expense of health serv-
ices. For instance, in 1999, the governments of sub-Saha-
ran Africa dedicated US$7 billion to military spending,
whereas, diverting just 15% of this would have raised
more than one US$ billion, enough to treat millions of
patients affected by neglected diseases[13,14]. It is also
worth stressing that, in the absence of reporting and sur-
veillance, the available statistics on the burden of NDs are
sometimes very different as indicated in Tables 2 and 3.
To overcome this odd situation and in order to reduce the
burden of neglected diseases afflicting mainly poor popu-
Table 4: New chemical entities (NCEs) approved between 1975 and 1999 by drug class and relative to disease burden and drug sales 
[9]
Therapeutic areas Approved NCEs 
1975–1999
Proportion of 
worldwide sales Year 
1999
NCEs by DALY Drug sales (millions of US$) by DALY
Central nervous system 211 (15·1%) 15·1% 1·32 193
Cardiovascular 179 (12·8%) 19·8% 1·25 283
Cytostatics (neoplasms) 111 (8·0%) 3·7% 1·31 90
Respiratory (non-infectious) 89 (6·4%) 9·3% 1·44 307
Anti-infectives and antiparasitics 224 (16·1%) 10·3% 0·55 52
HIV/AIDS 26 (1·9%) 1·5% 0·37 44
Tuberculosis 3 (0·2%) 0·2% 0·11 11
Tropical diseases (Total) 13 (0·9%) 0·2% 0·10 3
Malaria 4 (0·3%) 0·1% 0·10 5
Other therapeutic categories 579 (41·6%) 41·9% 1·10 163
Total 1393 (100%) 100% 1·01 148
Table 3: The burden of neglected diseases revised estimates (The Lancet) [6]
Disease Deaths Burden in DALYs (in million)
Hookworm diseases 22.1
Ascariasis 10.5
Trichuriasis 6.4
Lymphatic filariasis 0 5.8
Trachoma 0 2.3
Leishmaniasis 100 000 2.1
Schistosomiasis 150 000 -200 000 4.5
Sleeping sickness 100 000 1.5
Onchocerciasis 0 0.5
Chagas disease 14 000 0.7
Leprosy 6 000 0.2
Buruli ulcer NA
Total 500 000 56.6International Journal for Equity in Health 2007, 6:20 http://www.equityhealthj.com/content/6/1/20
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lations of developing countries, pragmatic and efficient
strategies are urgently needed. Beside large campaigns for
education and sensitisation, measures may include
advance purchase commitments, tax credits, fee waivers,
partial transfer of patent rights, innovation prizes, tech-
nology transfer, health innovation and various incentives
for investment. These would promote development of
drugs and vaccines for neglected diseases by enhancing
collaboration with the pharmaceutical industry of devel-
oped countries and encouraging research and develop-
ment for drugs in developing countries [1-5,10-15].
3. Conclusion
In many developing countries, millions of people live
with less than one dollar a day and on fragile and often
remote rural ecosystems, most of them lack access to basic
health services and safe drinking water and sanitation
(vectors that transmit NDs thrive on these ideal condi-
tions). Trapped in the vicious circle of underdevelopment-
poverty-health inequity, these populations constitute
exhausted "preys" for "predators" such as HIV/AIDS,
malaria, tuberculosis and a multitude of the so-called
neglected diseases. The growing attention given to the
"Big Three Killers" should not shadow the suffering that
neglected diseases are causing to millions of people who
can afford, at best, archaic drugs, some of which are toxic,
ineffective or difficult to administer.
In the era of science and high technology, while regular
meetings are held worldwide to discuss human rights and
various forms, causes and consequences of health inequi-
ties, it is a shame that poor populations living in develop-
ing countries are denied access to adequate and affordable
treatment against NDs. Urgent actions are needed to
develop new drugs and vaccines that are efficient and
accessible. A big challenge is addressed to national and
international decision makers but it is worth trying.
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their impact is given in this file.
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